Peritoneal Dialysis

Angiostatin improves ultrafiltration, physiology in dialysis dysfunction

Published in Gene Therapy Weekly, March 28th, 2002

by Sonia Nichols, senior medical writer - Peritoneal membrane dysfunction caused by long term peritoneal dialysis has the potential to be relieved with the use of adenovirus mediated angiostatin gene therapy.

A group at McMaster University in Hamilton, Ontario, Canada, has used angiostatin gene therapy in rodent models to show it not only improves ultrafiltration but also reduces excess vascularity in the peritoneum after peritoneal membrane failure. Peter J. Margetts and fellow investigators at McMaster believe that such therapy might mitigate peritoneum injury sometimes seen in patients on long-term dialysis.

In their research, the team designated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-03-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry